Kevin P. Hill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin P. Hill has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Roger D. Weiss
Division of Alcohol, Drugs and Addiction McLean Hospital Belmont Massachusetts USA
3 shared publications Matthew D. Palastro
2 shared publicationsBrian Johnson
State University of New York Upstate Medical University, Syracuse, New York
1 shared publication- Conor Kevin Farren
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
1 shared publication Garrett M. Fitzmaurice
Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts, 02478
1 shared publicationGeetha Subramaniam
Center for Clinical Trials Network, National Institute on Drug Abuse, Bethesda, Maryland, 20892
1 shared publication
Latest Publications
- 25 October 2017
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 127 (11) , 785-789
Medical cannabis for the treatment of chronic pain and other disorders: misconceptions and facts
Recently, many countries have enacted new cannabis policies, including decriminalization of cannabis possession, medical cannabis legalization, and legalization of recreational cannabis. In this context, patients and their physicians have had an increasing number of conversations about the risks and benefits of cannabis. While cannabis and cannabinoids continue to be evaluated as pharmacotherapy for medical conditions, currently, the best evidence exists for the following medical conditions: chronic pain, neuropathic pain, and spasticity resulting from multiple sclerosis. We also reviewed the current state of evidence for cannabis and cannabinoids for a number of other medical conditions while addressing the potential acute and chronic effects of cannabis use, which are issues that physicians must consider before making an official recommendation on the use of medical cannabis to a patient. As patient requests for medical cannabis increase, physicians must become knowledgeable on the science of medical cannabis and open to a discussion about why the patient feels that medical cannabis may be helpful to them.
- 25 October 2017
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 127 (11) , 785-789
Medical cannabis for the treatment of chronic pain and other disorders: misconceptions and facts
Recently, many countries have enacted new cannabis policies, including decriminalization of cannabis possession, medical cannabis legalization, and legalization of recreational cannabis. In this context, patients and their physicians have had an increasing number of conversations about the risks and benefits of cannabis. While cannabis and cannabinoids continue to be evaluated as pharmacotherapy for medical conditions, currently, the best evidence exists for the following medical conditions: chronic pain, neuropathic pain, and spasticity resulting from multiple sclerosis. We also reviewed the current state of evidence for cannabis and cannabinoids for a number of other medical conditions while addressing the potential acute and chronic effects of cannabis use, which are issues that physicians must consider before making an official recommendation on the use of medical cannabis to a patient. As patient requests for medical cannabis increase, physicians must become knowledgeable on the science of medical cannabis and open to a discussion about why the patient feels that medical cannabis may be helpful to them.
- Top Cited PapersOpen Access
- 1 January 2017
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 2 (1) , 96-104
Cannabis and Pain: A Clinical Review
Introduction: Cannabis has been used for medical purposes across the world for centuries. As states and countries implement medical and recreational cannabis policies, increasing numbers of people are using cannabis pharmacotherapy for pain. There is a theoretical rationale for cannabis' efficacy for pain management, although the subjective pain relief from cannabis may not match objective measurements of analgesia. As more patients turn to cannabis for pain relief, there is a need for additional scientific evidence to evaluate this increase. Materials and Methods: Research for this review was performed in the PubMed/National Library of Medicine database. Discussion: Preclinical studies demonstrate a narrow therapeutic window for cannabis as pharmacotherapy for pain; the body of clinical evidence for this indication is not as extensive. A recent meta-analysis of clinical trials of cannabis and cannabinoids for pain found modest evidence supporting the use of cannabinoid pharmacotherapy for pain. Recent epidemiological studies have provided initial evidence for a possible reduction in opioid pharmacotherapy for pain as a result of increased implementation of medical cannabis regimens. Conclusion: With increased use of medical cannabis as pharmacotherapy for pain comes a need for comprehensive risk-benefit discussions that take into account cannabis' significant possible side effects. As cannabis use increases in the context of medical and recreational cannabis policies, additional research to support or refute the current evidence base is essential to attempt to answer the questions that so many healthcare professionals and patients are asking.
- 1 January 2017
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 2 (1) , 96-104
Top Cited PapersOpen AccessCannabis and Pain: A Clinical Review
Introduction: Cannabis has been used for medical purposes across the world for centuries. As states and countries implement medical and recreational cannabis policies, increasing numbers of people are using cannabis pharmacotherapy for pain. There is a theoretical rationale for cannabis' efficacy for pain management, although the subjective pain relief from cannabis may not match objective measurements of analgesia. As more patients turn to cannabis for pain relief, there is a need for additional scientific evidence to evaluate this increase. Materials and Methods: Research for this review was performed in the PubMed/National Library of Medicine database. Discussion: Preclinical studies demonstrate a narrow therapeutic window for cannabis as pharmacotherapy for pain; the body of clinical evidence for this indication is not as extensive. A recent meta-analysis of clinical trials of cannabis and cannabinoids for pain found modest evidence supporting the use of cannabinoid pharmacotherapy for pain. Recent epidemiological studies have provided initial evidence for a possible reduction in opioid pharmacotherapy for pain as a result of increased implementation of medical cannabis regimens. Conclusion: With increased use of medical cannabis as pharmacotherapy for pain comes a need for comprehensive risk-benefit discussions that take into account cannabis' significant possible side effects. As cannabis use increases in the context of medical and recreational cannabis policies, additional research to support or refute the current evidence base is essential to attempt to answer the questions that so many healthcare professionals and patients are asking.
- Open Access
- 28 June 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (9) , 798-799
Recreational cannabis legalisation: details will determine mental health effects
- 28 June 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (9) , 798-799
Open AccessRecreational cannabis legalisation: details will determine mental health effects
- 1 July 2015
- Published by Elsevier in The Lancet Psychiatry
- Vol. 2 (7) , 572-573
Medical marijuana does not increase adolescent marijuana use
- 1 July 2015
- Published by Elsevier in The Lancet Psychiatry
- Vol. 2 (7) , 572-573
Medical marijuana does not increase adolescent marijuana use
- 1 September 2014
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 20 (5) , 389-391
Medical Marijuana
With 23 states and the District of Columbia having enacted medical marijuana laws as of August 2014, it is important that psychiatrists be able to address questions about medical marijuana from patients, families, and other health care professionals. The author discusses the medical literature on synthetic cannabinoids and medical marijuana. The synthetic cannabinoids dronabinol and nabilone are approved by the United States Food and Drug Administration for nausea and vomiting associated with cancer chemotherapy and appetite stimulation in patients with wasting diseases such as acquired immunodeficiency syndrome (AIDS). Results of clinical trials of these agents for other conditions have varied widely thus far. In addition, few data are available on the use of the marijuana plant as a medical treatment. The author concludes that there is a clear need for additional research on possible medical uses of cannabinoids. He notes that discussions with prospective medical marijuana patients should emphasize the importance of communication among all parties due to the possible side effects of treatment with marijuana and its potential to interact with other medications the patient may be taking. Facilitating a thorough substance abuse consultation is one of most positive ways that psychiatrists, especially addiction psychiatrists, can make an impact as medical marijuana becomes increasingly common. A careful review of the prospective medical marijuana user’s substance use history, co-occurring medical and psychiatric conditions, family history, and psychosocial stressors is essential in evaluating the potential risks of medical marijuana for these patients. The author concludes that psychiatrists can have a significant impact by increasing the likelihood that medical marijuana will be used in a safe and responsible way. (Journal of Psychiatric Practice 2014;20:389–391)
- 1 September 2014
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 20 (5) , 389-391
Medical Marijuana
With 23 states and the District of Columbia having enacted medical marijuana laws as of August 2014, it is important that psychiatrists be able to address questions about medical marijuana from patients, families, and other health care professionals. The author discusses the medical literature on synthetic cannabinoids and medical marijuana. The synthetic cannabinoids dronabinol and nabilone are approved by the United States Food and Drug Administration for nausea and vomiting associated with cancer chemotherapy and appetite stimulation in patients with wasting diseases such as acquired immunodeficiency syndrome (AIDS). Results of clinical trials of these agents for other conditions have varied widely thus far. In addition, few data are available on the use of the marijuana plant as a medical treatment. The author concludes that there is a clear need for additional research on possible medical uses of cannabinoids. He notes that discussions with prospective medical marijuana patients should emphasize the importance of communication among all parties due to the possible side effects of treatment with marijuana and its potential to interact with other medications the patient may be taking. Facilitating a thorough substance abuse consultation is one of most positive ways that psychiatrists, especially addiction psychiatrists, can make an impact as medical marijuana becomes increasingly common. A careful review of the prospective medical marijuana user’s substance use history, co-occurring medical and psychiatric conditions, family history, and psychosocial stressors is essential in evaluating the potential risks of medical marijuana for these patients. The author concludes that psychiatrists can have a significant impact by increasing the likelihood that medical marijuana will be used in a safe and responsible way. (Journal of Psychiatric Practice 2014;20:389–391)
- 1 September 2013
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 132 (1-2) , 342-345
Association of cannabis use with opioid outcomes among opioid-dependent youth
- 1 September 2013
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 132 (1-2) , 342-345
Association of cannabis use with opioid outcomes among opioid-dependent youth
- 1 October 2012
- Vol. 61 (10) , 588-97
Diagnosing and treating opioid dependence.
The surge in opioid abuse highlights the importance of questioning patients about their use of prescription analgesics--and knowing when and how to intervene.
- 1 October 2012
- Vol. 61 (10) , 588-97
Diagnosing and treating opioid dependence.
The surge in opioid abuse highlights the importance of questioning patients about their use of prescription analgesics--and knowing when and how to intervene.
- 15 September 2012
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 14 (6) , 659-666
Bipolar Disorder and Alcohol Use Disorder: A Review
Bipolar disorder and alcohol use disorder represent a significant comorbid population, which is significantly worse than either diagnosis alone in presentation, duration, co-morbidity, cost, suicide rate, and poor response to treatment. They share some common characteristics in relation to genetic background, neuroimaging findings, and some biochemical findings. They can be treated with separate care, or ideally some form of integrated care. There are a number of pharmacotherapy trials, and psychotherapy trials that can aid program development. Post-treatment prognosis can be influenced by a number of factors including early abstinence, baseline low anxiety, engagement with an aftercare program and female gender. The future development of novel therapies relies upon increased psychiatric and medical awareness of the co-morbidity, and further research into novel therapies for the comorbid group.
- 15 September 2012
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 14 (6) , 659-666
Bipolar Disorder and Alcohol Use Disorder: A Review
Bipolar disorder and alcohol use disorder represent a significant comorbid population, which is significantly worse than either diagnosis alone in presentation, duration, co-morbidity, cost, suicide rate, and poor response to treatment. They share some common characteristics in relation to genetic background, neuroimaging findings, and some biochemical findings. They can be treated with separate care, or ideally some form of integrated care. There are a number of pharmacotherapy trials, and psychotherapy trials that can aid program development. Post-treatment prognosis can be influenced by a number of factors including early abstinence, baseline low anxiety, engagement with an aftercare program and female gender. The future development of novel therapies relies upon increased psychiatric and medical awareness of the co-morbidity, and further research into novel therapies for the comorbid group.